Physiologically Based Pharmacokinetic Modeling

This book describes the application of physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of therapeutic monoclonal antibodies (MAbs). These macromolecules exhibit distinctly different pharmacokinetic features compared with conventional small-molecule drugs. A PBPK model was developed to characterize the biodistribution of the pancarcinoma MAb CC49 in normal and neoplastic tissues of nude mice. The model included all the major processes involved in determining the disposition characteristics of MAbs. The applicability of the model was tested by predicting the disposition of di- and tetravalent scFv constructs of CC49 in mice. Further, the model was applied to study the differences in disposition between Mabs labeled with 125I and 177Lu. Finally, the clinical utility of the model was tested by attempting to predict the disposition and tumor uptake of CC49 in patients. This model may be used to study the biodistribution and tumor localization of different combinations of radionuclides and engineered antibody fragments in an effort to establish the most effective approach to achieve the optimal therapeutic ratio for tumor therapy.

Autorentext

Jasmine Davda received her MS and Ph.D. in Pharmaceutical Sciences from the University of Nebraska in 2000 and 2007, respectively. Between 2001 and 2004, Dr. Davda was Research Scientist at Piramal Life Sciences, India. In 2007, Dr. Davda joined Eli Lilly & Co. in Indianapolis, USA, where she is Research Scientist in Drug Disposition.